402958-22-9Relevant academic research and scientific papers
Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor
Yip, Yvonne,Victor, Frantz,Lamar, Jason,Johnson, Robert,Wang, Q. May,Barket, Donna,Glass, John,Jin, Ling,Liu, Lifei,Venable, Daryl,Wakulchik, Mark,Xie, Congping,Heinz, Beverly,Villarreal, Elcira,Colacino, Joe,Yumibe, Nathan,Tebbe, Mark,Munroe, John,Chen, Shu-Hui
, p. 251 - 256 (2004)
We describe herein the design, syntheses and evaluation of a number of bicycloproline P2 bearing HCV protease inhibitors endowed with impressive enzyme potency, enzyme selectivity, cellular activity and favorable ADME profiles.
3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease
-
Page/Page column 118-119, (2008/06/13)
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
